Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.

@article{Moreau2016OralIL,
  title={Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.},
  author={Philippe Moreau and Tamas Masszi and Norbert Grząśko and Nizar Jacques Bahlis and Markus Hansson and Luděk Pour and Irwindeep Sandhu and P. S. Ganly and Bartrum W Baker and Sharon R. Jackson and A M Stoppa and David R Simpson and Peter Gimsing and Antonio Palumbo and Laurent Garderet and Michele Cavo and S K Praveen Kumar and Cyrille Touzeau and Francis K Buadi and Jacob P Laubach and Deborah T Berg and Jianchang Lin and Alessandra di Bacco and A M Hui and Helgi J K van de Velde and Paul G Richardson},
  journal={The New England journal of medicine},
  year={2016},
  volume={374 17},
  pages={1621-34}
}
BACKGROUND Ixazomib is an oral proteasome inhibitor that is currently being studied for the treatment of multiple myeloma. METHODS In this double-blind, placebo-controlled, phase 3 trial, we randomly assigned 722 patients who had relapsed, refractory, or relapsed and refractory multiple myeloma to receive ixazomib plus lenalidomide-dexamethasone (ixazomib group) or placebo plus lenalidomide-dexamethasone (placebo group). The primary end point was progression-free survival. RESULTS… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 124 times over the past 90 days. VIEW TWEETS

Citations

Publications citing this paper.
Showing 1-10 of 131 extracted citations

References

Publications referenced by this paper.
Showing 1-10 of 31 references

Multiple myeloma

  • C Röllig, S Knop, M. Bornhäuser
  • 2015
Highly Influential
7 Excerpts

Discrete sequential boundaries for clinical trials

  • Lan KKG, DL Demets
  • Biometrika
  • 1983
Highly Influential
7 Excerpts

Carfilzomib, lenalidomide, The New England Journal of Medicine Downloaded from nejm.org on December 14, 2016

  • AK Stewart, SV Rajkumar, MA Dimopoulos
  • For personal use only. No other uses without…
  • 2016
1 Excerpt

Impact of cytogenetics on outcomes of transplant-ineligible patients with newly diagnosed multiple myeloma treated with continuous lenalidomide plus low-dose dexamethasone in the first (MM-020) trial

  • H Avet-Loiseau, C Hulin, L Benboubker
  • Blood 2015;
  • 2015
2 Excerpts

Similar Papers

Loading similar papers…